Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEO-PV-01 + carboplatin + pembrolizumab + pemetrexed
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
NEO-PV-01 + carboplatin + pembrolizumab + pemetrexed is a combination therapy consisting of a personalized neoantigen vaccine (NEO-PV-01) with standard chemotherapy (carboplatin and pemetrexed) and an immune checkpoint inhibitor (pembrolizumab). This regimen is designed for the treatment of advanced non-squamous non-small cell lung cancer (NSCLC) as first-line therapy. NEO-PV-01 targets specific mutations in tumor DNA to create a customized treatment approach for each patient, while pembrolizumab blocks the PD-1 pathway to enhance anti-tumor immune responses, and the chemotherapy agents directly attack cancer cells.
- Brand names
- KeytrudaAlimta
- Other names
- Personalized neoantigen vaccine + anti-PD1 + chemotherapyNEO-PV-01 + pemetrexed + carboplatin + pembrolizumab
02
Targets
TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on NEO-PV-01 + carboplatin + pembrolizumab + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEO-PV-01 + carboplatin + pembrolizumab + pemetrexed.